FIELD: medicine; ophthalmology.
SUBSTANCE: invention can be used to predict an unfavorable response to anti-VEGF therapy for macular neovascularization. 2 weeks before anti-VEGF therapy, the intraocular pressure value is determined on the affected eye using a non-contact method. When its value is more than 21 mm Hg an unfavorable response to anti-VEGF therapy is predicted.
EFFECT: invention makes it possible to evaluate the feasibility of anti-VEGF therapy for macular neovascularization.
1 cl, 2 dwg, 1 tbl, 3 ex
Authors
Dates
2024-01-09—Published
2023-06-21—Filed